BUZZ-Oklo rises; BofA says Meta deal signals 'meaningful step forward'
I'm PortAI, I can summarize articles.
Shares of Oklorose 3.5% to $93.06 after BofA Securities upgraded its rating to "buy" from "neutral". This follows Oklo's agreement with Meta to develop a 1.2 GW advanced nuclear campus, with Meta prepaying $25 million for phase 1. BofA raised the price target to $127 from $111, noting Oklo's transition to an "actively financed" development pipeline. Currently, 13 of 19 brokerages rate the stock as "buy" or higher, with a median price target of $124.50. Oklo shares have more than tripled in 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments